SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
50978Sooner than later imported (from Asia) API price will increase on its own, due Miljenko Zuanic-6/17/2019
50977The damage from a 25% tariff on China’s API would be most severe for companies wDewDiligence_on_SI-6/17/2019
50976<Inasmuch as China is the API source for the large majority of drugs sold in Miljenko Zuanic-6/17/2019
50975One item that hasn’t received much discussion: Pharmaceuticals—and API—will be oDewDiligence_on_SI-6/17/2019
50974I noticed general overall strength today in biotech stocks. Is this related to Art Bechhoefer-6/17/2019
50973This is cool - a mechanism to genetically transmit neuronal information across gnigel bates36/7/2019
50972Way Off Topic. TED talk by investigative journalist regarding Facebook, CambridA.J. Mullen16/2/2019
50971Saw your post while doing a search here on NSAIDs. RE exercise and arrhythmia. semi_infinite 36/1/2019
50970Derek Lowe isn't impressed and i agree lol blogs.sciencemag.orglinhtu-5/31/2019
50969Research confirms gut-brain connection in autism eurekalert.orgbiocqr-5/30/2019
50968The time intervals cited in the iHub AMRN post are not absolute mandates for theDewDiligence_on_SI15/30/2019
50967AMRN -- Advisory Committee Is the upshot of this IHub post accurate? It's quidditch-5/30/2019
50966If Interested in the GLPG Phase 3 program this paper just out. Dr. Maher I beghmm15/22/2019
50965There are additional results this weekend. Might as well wait for those. Bad dayJamesK-5/21/2019
50964The Medicines Co up only 2.8% on favorable LT safety, infrequent dosing, and impkeokalani'nui-5/20/2019
50963They both reported results in August 2017 and Fibrogen is now well behind.JamesK-5/19/2019
50962New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in PersA.J. Mullen-5/19/2019
50961MDCO ALNY presented Inclisiran results over the weekend. Seems to be pretty freeJamesK-5/19/2019
50960You gave a couple ideas about why it might be slow to enroll. I thought the trikeokalani'nui-5/18/2019
50959Cryptic...I like it. Still, too little to go on for me. What's your poinatticus4paws-5/18/2019
50958clinicaltrials.gov keokalani'nui-5/18/2019
50957Yes, FGEN's trial will run a little longer and of course start recruiting 3 atticus4paws-5/18/2019
50956Note that the GLPG completion date is more than a year before FGEN.JamesK-5/18/2019
50955Good stuff! Thanks!atticus4paws-5/17/2019
50954I saw press releases calling GLPG's phase 2, a phase 2A. I couldn't findghmm25/17/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News